Summary & Overview
CPT 81414: Genetic Testing for Cardiac Ion Channelopathies
CPT code 81414 represents a specialized genetic testing procedure for cardiac ion channelopathies, including conditions such as Brugada syndrome and long QT syndrome. This code is used for duplication and deletion gene analysis panels, requiring the inclusion of at least two genes—KCNH2 and KCNQ1—to help diagnose and manage patients with inherited cardiac arrhythmias. The service is typically performed in a laboratory setting and falls under the category of molecular pathology.
Nationally, this code is significant due to its role in identifying genetic risk factors for potentially life-threatening cardiac conditions. Coverage for CPT code 81414 is provided by major payers including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, reflecting broad acceptance of this testing in clinical practice.
Readers will gain insights into payer coverage, clinical indications, and the operational context for this genetic test. The publication also addresses relevant modifiers, associated taxonomies, and ICD-10 diagnoses commonly linked to this procedure. Additionally, comparisons to related CPT codes, such as 81413, are provided to clarify distinctions in genetic testing panels. This summary offers a comprehensive overview of policy updates, clinical benchmarks, and billing considerations for CPT code 81414.
CPT Code Overview
CPT code 81414 is used for genetic testing related to cardiac ion channelopathies, such as Brugada syndrome, long QT syndrome, short QT syndrome, and catecholaminergic polymorphic ventricular tachycardia. This code specifically covers duplication and deletion gene analysis panels, which must include analysis of at least two genes, including KCNH2 and KCNQ1. The service type is molecular pathology / genetic testing, and the typical site of service is a laboratory (POS 81). This testing plays a crucial role in identifying genetic causes of certain cardiac arrhythmias and syndromes, supporting clinical decision-making and patient management.
Clinical & Coding Specifications
Clinical Context
A patient presents with symptoms suggestive of a cardiac ion channelopathy, such as unexplained syncope, palpitations, or a family history of sudden cardiac death. The cardiologist suspects conditions like Brugada syndrome, long QT syndrome, short QT syndrome, or catecholaminergic polymorphic ventricular tachycardia. To confirm the diagnosis and guide management, the provider orders a duplication/deletion gene analysis panel, specifically targeting at least two genes including KCNH2 and KCNQ1. The specimen is sent to a clinical laboratory (Place of Service 81) for molecular pathology testing. Results inform clinical decision-making regarding risk stratification, treatment, and family screening.
Coding Specifications
-
Modifiers:
26: Professional Component – Used when only the interpretation of the test is performed by the provider.TC: Technical Component – Used when only the technical aspect (e.g., running the test in the lab) is performed.91: Repeat Clinical Diagnostic Laboratory Test – Used when the same test is repeated on the same patient for clinical reasons.
-
Provider Taxonomies:
| Taxonomy Code | Specialty Name |
|---|---|
207ZP0102X | Pathology |
207L00000X | Clinical Laboratory |
207Q00000X | Family Medicine Physician |
- Specialties Represented:
- Pathologists
- Clinical laboratory professionals
- Family medicine physicians (may order or interpret results)
Related Diagnoses
E75.21: Other disorders of sphingolipid metabolism–GM2 gangliosidosis- Relevant for patients with metabolic disorders that may present with cardiac symptoms.
I45.81: Long QT syndrome- Directly related; genetic testing is indicated for diagnosis and management.
I49.8: Other specified cardiac arrhythmias- Used when arrhythmias are present but not classified elsewhere; genetic testing may clarify etiology.
I42: Cardiomyopathy- Broad category; genetic testing may be indicated for unexplained cardiomyopathy.
I42.0: Dilated cardiomyopathy- Specific subtype; genetic analysis may help identify underlying causes.
I42.1: Obstructive hypertrophic cardiomyopathy- Relevant for patients with hypertrophic changes; genetic testing can inform risk.
I42.2: Other hypertrophic cardiomyopathy- Includes other forms; genetic testing may be part of workup.
I42.5: Other restrictive cardiomyopathy- For restrictive types; genetic analysis may be considered.
E78.01: Pure hypercholesterolemia, familial- Familial hypercholesterolemia may coexist with cardiac channelopathies; genetic testing can be part of comprehensive cardiac risk assessment.
Related CPT Codes
81413: Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia); genomic sequence analysis panel, must include sequencing of at least 10 genes
Relation to 81414:
81413is a broader genomic sequence analysis panel, typically used when a more comprehensive genetic evaluation is needed, including sequencing of at least 10 genes.81414is focused on duplication/deletion analysis of at least 2 genes, including KCNH2 and KCNQ1.- In clinical workflow,
81413may be used as an alternative or in conjunction with81414depending on the depth of genetic analysis required.
National Reimbursement Benchmarks
For CPT code 81414, national mean rates among commercial payers (BUCA) average $517.41, which is notably higher than typical Medicare rates for similar codes, though Medicare data is not available in the input for direct comparison. Among individual commercial payers, Cigna reports the highest mean rate at $576.68, while Aetna is lowest at $491.09.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies significantly across payers. UnitedHealth Group shows the widest spread ($299.25), indicating greater variability in contracted rates. In contrast, Aetna has the tightest range ($176.00), suggesting more consistent reimbursement levels. Cigna also exhibits a wide range ($453.33), reflecting substantial rate variability. The table and chart below present the full breakdown of national benchmarks for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.